Harvoni and Epclusa are both prescription medications used to treat chronic hepatitis C virus (HCV) infection.
Harvoni is a combination of ledipasvir and sofosbuvir, two antiviral medications that target HCV. It is indicated for the treatment of HCV genotypes 1, 4, 5 and 6.
Epclusa, on the other hand, is a combination of sofosbuvir and velpatasvir, two antiviral medications that target HCV. It is indicated for the treatment of all HCV genotypes (1-6).
The main difference between Harvoni and Epclusa is the type of antiviral medications they contain and the number of HCV genotypes they are indicated to treat. Both medications can lead to high cure rates and have similar side effect profiles.
However, the choice of medication for a specific patient will depend on factors such as the HCV genotype, overall health, and previous treatment history.